| Long‐term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection T Hosaka, F Suzuki, M Kobayashi, Y Seko, Y Kawamura, H Sezaki, ... Hepatology 58 (1), 98-107, 2013 | 806 | 2013 |
| Management of hepatocellular carcinoma in Japan: JSH consensus statements and recommendations 2021 update M Kudo, Y Kawamura, K Hasegawa, R Tateishi, K Kariyama, S Shiina, ... Liver cancer 10 (3), 181-223, 2021 | 409 | 2021 |
| Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino … N Akuta, F Suzuki, Y Kawamura, H Yatsuji, H Sezaki, Y Suzuki, T Hosaka, ... Journal of hepatology 46 (3), 403-410, 2007 | 322 | 2007 |
| Sustained virological response reduces incidence of onset of type 2 diabetes in chronic hepatitis C Y Arase, F Suzuki, Y Suzuki, N Akuta, M Kobayashi, Y Kawamura, ... Hepatology 49 (3), 739-744, 2009 | 317 | 2009 |
| Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin N Akuta, F Suzuki, M Hirakawa, Y Kawamura, H Yatsuji, H Sezaki, ... Hepatology 52 (2), 421-429, 2010 | 316 | 2010 |
| Large-scale long-term follow-up study of Japanese patients with non-alcoholic Fatty liver disease for the onset of hepatocellular carcinoma Y Kawamura, Y Arase, K Ikeda, Y Seko, N Imai, T Hosaka, M Kobayashi, ... Official journal of the American College of Gastroenterology| ACG 107 (2 …, 2012 | 297 | 2012 |
| Effect of type 2 diabetes on risk for malignancies includes hepatocellular carcinoma in chronic hepatitis C Y Arase, M Kobayashi, F Suzuki, Y Suzuki, Y Kawamura, N Akuta, ... Hepatology 57 (3), 964-973, 2013 | 251 | 2013 |
| Long-term continuous entecavir therapy in nucleos (t) ide-naïve chronic hepatitis B patients A Ono, F Suzuki, Y Kawamura, H Sezaki, T Hosaka, N Akuta, ... Journal of hepatology 57 (3), 508-514, 2012 | 199 | 2012 |
| The Japanese clinical practice guidelines for management of sepsis and septic shock 2020 (J-SSCG 2020) M Egi, H Ogura, T Yatabe, K Atagi, S Inoue, T Iba, Y Kakihana, ... Journal of intensive care 9, 1-144, 2021 | 182 | 2021 |
| Viral elimination reduces incidence of malignant lymphoma in patients with hepatitis C Y Kawamura, K Ikeda, Y Arase, H Yatsuji, H Sezaki, T Hosaka, N Akuta, ... The American journal of medicine 120 (12), 1034-1041, 2007 | 167 | 2007 |
| Low risk of adefovir resistance in lamivudine-resistant chronic hepatitis B patients treated with adefovir plus lamivudine combination therapy: two-year follow-up H Yatsuji, F Suzuki, H Sezaki, N Akuta, Y Suzuki, Y Kawamura, T Hosaka, ... Journal of hepatology 48 (6), 923-931, 2008 | 156 | 2008 |
| Sustained virologic response by direct antiviral agents reduces the incidence of hepatocellular carcinoma in patients with HCV infection M Kobayashi, F Suzuki, S Fujiyama, Y Kawamura, H Sezaki, T Hosaka, ... Journal of medical virology 89 (3), 476-483, 2017 | 148 | 2017 |
| Prevalence of hepatitis C virus variants resistant to NS3 protease inhibitors or the NS5A inhibitor (BMS-790052) in hepatitis patients with genotype 1b F Suzuki, H Sezaki, N Akuta, Y Suzuki, Y Seko, Y Kawamura, T Hosaka, ... Journal of Clinical Virology 54 (4), 352-354, 2012 | 131 | 2012 |
| Amino acid substitutions in the hepatitis C virus core region are the important predictor of hepatocarcinogenesis N Akuta, F Suzuki, Y Kawamura, H Yatsuji, H Sezaki, Y Suzuki, T Hosaka, ... Hepatology 46 (5), 1357-1364, 2007 | 130 | 2007 |
| Predictors of viral kinetics to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b N Akuta, F Suzuki, Y Kawamura, H Yatsuji, H Sezaki, Y Suzuki, T Hosaka, ... Journal of medical virology 79 (11), 1686-1695, 2007 | 127 | 2007 |
| The Obesity and Fatty Liver Are Reduced by Plant-Derived Pediococcus pentosaceus LP28 in High Fat Diet-Induced Obese Mice X Zhao, F Higashikawa, M Noda, Y Kawamura, Y Matoba, T Kumagai, ... PLoS One 7 (2), e30696, 2012 | 114 | 2012 |
| Influence of ITPA polymorphisms on decreases of hemoglobin during treatment with pegylated interferon, ribavirin, and telaprevir F Suzuki, Y Suzuki, N Akuta, H Sezaki, M Hirakawa, Y Kawamura, ... Hepatology 53 (2), 415-421, 2011 | 114 | 2011 |
| Effects of a sodium‐glucose cotransporter 2 inhibitor in nonalcoholic fatty liver disease complicated by diabetes mellitus: preliminary prospective study based on serial liver … N Akuta, C Watanabe, Y Kawamura, Y Arase, S Saitoh, S Fujiyama, ... Hepatology communications 1 (1), 46-52, 2017 | 113 | 2017 |
| HBcrAg is a predictor of post‐treatment recurrence of hepatocellular carcinoma during antiviral therapy T Hosaka, F Suzuki, M Kobayashi, M Hirakawa, Y Kawamura, H Yatsuji, ... Liver International 30 (10), 1461-1470, 2010 | 107 | 2010 |
| Poor response to pegylated interferon and ribavirin in older women infected with hepatitis C virus of genotype 1b in high viral loads H Sezaki, F Suzuki, Y Kawamura, H Yatsuji, T Hosaka, N Akuta, ... Digestive diseases and sciences 54, 1317-1324, 2009 | 107 | 2009 |
